Article
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.
Cell - 3 May 2018
McMillan Elizabeth A, Ryu Myung-Jeom, Diep Caroline H, Mendiratta Saurabh, Clemenceau Jean R, Vaden Rachel M, Kim Ju-Hwa, Motoyaji Takashi, Covington Kyle R, Peyton Michael, Huffman Kenneth, Wu Xiaofeng, Girard Luc, Sung Yeojin, Chen Pei-Hsaun, Mallipeddi Prema L, Lee Joo Young, Hanson Jordan, Voruganti Sukesh, Yu Yunku, Park Sunho, Sudderth Jessica, DeSevo Christopher, Muzny Donna M, Doddapaneni HarshaVardhan, Gazdar Adi, Gibbs Richard A, Hwang Tae-Hyun, Heymach John V, Wistuba Ignacio, Coombes Kevin R, Williams Noelle S, Wheeler David A, MacMillan John B, Deberardinis Ralph J, Roth Michael G, Posner Bruce A, Minna John D, Kim Hyun Seok, White Michael A
Abstract excerpt
Diversity in the genetic lesions that cause cancer is extreme. In consequence, a pressing challenge is the development of drugs that target patient-specific disease mechanisms. To address this challenge, we employed a chemistry-first discovery paradigm for de novo identification of druggable targets linked to robust patient selection hypotheses. In particular, a 200,000 compound diversity-oriented chemical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.